Compare StocksABBV vs AEE

AbbVie Inc. (ABBV) vs Ameren Corporation (AEE): Which Is the Better Buy in 2026?

As of 2026-06-19, ABBV is overvalued at $216, with a DCF intrinsic value of $160 and a margin of safety of -35%. AEE is overvalued at $109, with an intrinsic value of $0 and a margin of safety of -100%. Of the two, ABBV has the wider margin of safety.

ABBV
AbbVie Inc.
$216.49
VS
AEE
Ameren Corporation
$108.67

Rewards

ABBV
  • AbbVie Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • Gross margin of 72.0% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • AbbVie Inc. scores 82/100 on the Economic Moat Score (Wide Moat), with reinvestment efficiency as the strongest competitive dimension.
AEE

    Risks

    ABBV
    • Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
    • FCF yield of 5.4% suggests reasonable valuation assuming continued moderate growth.
    • Trailing P/E of 105.6x is 69% above the historical average of 62.3x — the stock trades at a premium to its own history.
    AEE
    • PEG ratio of 2.58 indicates the stock is expensive relative to its expected growth — the market may be pricing in more growth than analysts project.
    • High leverage (1.56x net debt/equity) combined with thin interest coverage (-1.0x) poses financial risk.
    • Net debt/EBITDA of 5.6x indicates heavy leverage — it would take over 4 years of EBITDA to pay off net debt.

    Key Valuation Metrics

    Learn more →
    ABBV
    AEE
    Valuation
    $20.81B
    Free Cash Flow
    $-1.87B
    5.44%
    FCF Yield
    -6.22%
    105.60
    Trailing P/E
    19.54
    13.32
    Forward P/E
    18.71
    Quality & Moat
    21.89%
    ROIC
    5.36%
    N/A
    ROE
    11.75%
    72.03%
    Gross Margin
    50.45%
    0.61
    PEG Ratio
    2.58
    Balance Sheet Safety
    N/A
    Net Debt / Equity
    1.56
    N/A
    Interest Coverage
    N/A
    2.12
    Net Debt / EBITDA
    5.56
    3.11%
    Dividend Yield
    2.64%
    ABBV: 8Ties: 1AEE: 1
    ABBVAEE

    Historical Fundamentals

    Learn more →
    ABBV

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    AEE

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    ABBV
    N/A
    Net losses over 3 years — test not applicable
    Company had negative cumulative retained earnings
    Σ Retained
    $-19.85B
    Δ Market Cap
    +$118.02B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    AEE
    Not enough historical data to compute the retained earnings test.

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    ABBV
    35.3% Overvalued
    Price is 35.3% above estimated fair value
    Current Price: $216.49
    Fair Value: $160.05
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    AEE
    Insufficient Data
    Enter initial FCF to calculate intrinsic value
    Current Price: $108.67
    Fair Value: $0.00
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    ABBV

    What growth rate is the market pricing in at $216?

    +17.1%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +8.7%

    The market implies +17.1% Owner Earnings growth, above historical trends.

    Standard FCF implies a demanding +8.7%, reflecting heavy growth investment.

    AEE

    Requires positive FCF to compute implied growth rate.

    Economic Moat Score

    Learn more →
    ABBV
    82/100
    Wide Moat
    70+ Wide · 40-69 Narrow · <40 None

    Wide moat with strength across all dimensions. Reinvestment Efficiency is the standout factor.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
    AEE
    39/100
    No Moat
    70+ Wide · 40-69 Narrow · <40 None

    No durable moat detected, though margin stability shows some competitive positioning. The business lacks consistent evidence of sustainable advantages.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

    Forensic Accounting

    Learn more →
    ABBV
    -2.86
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
    AEE

    Insufficient data for Beneish M-Score calculation (requires 2+ years).

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    ABBV
    Insiders 0.1%Institutions 76.9%Retail & Other 23.0%
    No. of Institutional Holders5,106
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    AEE
    Insiders 0.3%Institutions 86.3%Retail & Other 13.4%
    No. of Institutional Holders1,236
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    ABBV
    0
    Buys (3M)
    0
    Buys (12M)
    No open market insider purchases found.
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    AEE
    0
    Buys (3M)
    0
    Buys (12M)
    No open market insider purchases found.
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    ABBV
    0
    Sells (3M)
    5
    Sells (12M)
    Total value (12M): $21.79M
    PURDUE DAVID R.
    Officer
    $1.22M
    @ $233.56 · 2026-03-04
    SIATIS PERRY C.
    General Counsel
    $4.38M
    @ $234.39 · 2026-03-02
    SIATIS PERRY C.
    General Counsel
    $5.15M
    @ $230.00 · 2026-02-25
    SALEKI-GERHARDT AZITA
    Chief Operating Officer
    $8.41M
    @ $198.42 · 2025-08-12
    DONOGHOE NICHOLAS
    Officer
    $2.64M
    @ $198.51 · 2025-08-05
    STEWART JEFFREY RYAN
    Officer
    $12.36M
    @ $210.08 · 2025-03-31
    REENTS SCOTT T.
    Chief Financial Officer
    $3.75M
    @ $212.34 · 2025-03-14
    GONZALEZ RICHARD A
    Director
    $20.26M
    @ $205.45 · 2025-03-03
    SIATIS PERRY C.
    General Counsel
    $5.82M
    @ $208.69 · 2025-03-03
    RICHMOND TIMOTHY J
    Officer
    $4.47M
    @ $210.45 · 2025-03-03
    BUCKBEE KEVIN K
    Officer
    $3.85M
    @ $203.41 · 2025-02-26
    RICHMOND TIMOTHY J
    Officer
    $6.07M
    @ $202.90 · 2025-02-26
    SIATIS PERRY C.
    General Counsel
    $1.14M
    @ $197.90 · 2025-02-20
    BUCKBEE KEVIN K
    Officer
    $310,032
    @ $172.24 · 2024-12-16
    GONZALEZ RICHARD A
    Officer and Director
    $12.40M
    @ $186.52 · 2024-08-05
    GONZALEZ RICHARD A
    Officer and Director
    $49.50M
    @ $175.00 · 2024-07-17
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    AEE
    2
    Sells (3M)
    19
    Sells (12M)
    Total value (12M): $8.58M
    SHAW THERESA A
    Officer
    $199,476
    @ $109.30 · 2026-05-14
    MOEHN MICHAEL L
    Officer
    $738,595
    @ $113.63 · 2026-05-01
    LINDGREN MARK C
    Officer of Subsidiary Company
    $231,844
    @ $111.84 · 2026-03-03
    SCHUKAR SHAWN E
    Officer of Subsidiary Company
    $556,404
    @ $111.84 · 2026-03-03
    LYONS MARTIN J JR
    Chief Executive Officer
    $3.00M
    @ $111.84 · 2026-03-03
    FLORES RAFAEL
    Director
    $178,432
    @ $111.52 · 2026-02-17
    MIZELL GWENDOLYN G.
    Officer of Subsidiary Company
    $393,473
    @ $110.90 · 2026-02-17
    SHAW THERESA A
    Officer
    $36,364
    @ $111.89 · 2026-02-17
    MOEHN MICHAEL L
    Officer
    $673,400
    @ $103.60 · 2026-02-02
    FLORES RAFAEL
    Director
    $23,672
    @ $105.21 · 2025-11-17
    FLORES RAFAEL
    Director
    $65,930
    @ $105.32 · 2025-11-17
    SHAW THERESA A
    Officer
    $34,050
    @ $104.77 · 2025-11-14
    SMITH PATRICK E.
    Officer
    $251,939
    @ $104.80 · 2025-11-14
    HARSHMAN RICHARD J
    Director
    $262,250
    @ $104.90 · 2025-11-14
    MOEHN MICHAEL L
    Chief Financial Officer
    $659,360
    @ $101.44 · 2025-11-03
    LINDGREN MARK C
    Officer of Subsidiary Company
    $353,115
    @ $100.89 · 2025-09-12
    MIZELL GWENDOLYN G.
    Officer of Subsidiary Company
    $149,250
    @ $99.50 · 2025-09-03
    MIZELL GWENDOLYN G.
    Officer of Subsidiary Company
    $101,790
    @ $101.79 · 2025-08-22
    MOEHN MICHAEL L
    Chief Financial Officer
    $666,510
    @ $102.54 · 2025-08-01
    MOEHN MICHAEL L
    Chief Financial Officer
    $641,030
    @ $98.62 · 2025-05-20
    LINDGREN MARK C
    Officer of Subsidiary Company
    $194,087
    @ $103.79 · 2025-03-04
    NWAMU CHONDA J.
    Officer
    $557,535
    @ $101.37 · 2025-03-04
    SCHUKAR SHAWN E
    Officer of Subsidiary Company
    $492,276
    @ $103.79 · 2025-03-04
    LYONS MARTIN J JR
    Chief Executive Officer
    $1.54M
    @ $103.79 · 2025-03-04
    SHAW THERESA A
    Officer
    $99,530
    @ $99.53 · 2025-02-26
    MOEHN MICHAEL L
    Chief Financial Officer
    $634,010
    @ $97.54 · 2025-02-20
    FLORES RAFAEL
    Director
    $186,067
    @ $97.93 · 2025-02-19
    IVEY CRAIG S
    Director
    $266,901
    @ $98.27 · 2025-02-19
    MOEHN MICHAEL L
    Chief Financial Officer
    $598,975
    @ $92.15 · 2024-11-20
    NWAMU CHONDA J.
    General Counsel
    $131,923
    @ $81.94 · 2024-08-28
    MOEHN MICHAEL L
    Chief Financial Officer
    $536,445
    @ $82.53 · 2024-08-20
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    ABBV
    FearGreed
    😐Neutral(56/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    AEE
    FearGreed
    😐Neutral(59/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    ABBV
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (56)
    AEE
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (59)
    View ABBV Full AnalysisView AEE Full Analysis

    Frequently Asked Questions: ABBV vs AEE

    Is AbbVie Inc. or Ameren Corporation more undervalued in 2026?

    Based on our discounted cash flow model, ABBV trades at a -35.3% margin of safety (intrinsic value $160 vs. price $216), compared to AEE's -100.0% margin of safety (intrinsic $0 vs. $109).

    Which stock has a wider economic moat, AbbVie Inc. or Ameren Corporation?

    ABBV scores 82/100 (Wide moat), while AEE scores 39/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Is Ameren Corporation in financial distress?

    AEE's Altman Z-Score of 0.9 places it in the Distress zone, signaling elevated bankruptcy risk. ABBV scores 2.4 (Grey zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

    Which company has better free cash flow, AbbVie Inc. or Ameren Corporation?

    AbbVie Inc. (ABBV) generates a 5.4% free cash flow yield, compared to Ameren Corporation's -6.2%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

    Which stock has higher return on invested capital, AbbVie Inc. or Ameren Corporation?

    ABBV earns 21.9% ROIC versus AEE's 5.4%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

    Which dividend is safer, AbbVie Inc.'s or Ameren Corporation's?

    AEE's dividend earns a safety score of 59/100 (Borderline), compared to ABBV's 39/100 (Unsafe). AEE has raised its dividend for 3 consecutive years.

    ABBV vs AEE: Which Is the Better Buy in 2026? | SafetyMargin.io